PKTX Quote, Financials, Valuation and Earnings

GB Sciences, Inc. has a net margin of -- compared to Protokinetix, Inc.'s net margin of --. Protokinetix, Inc.'s return on equity of -111.59% beat GB Sciences, Inc.'s return on equity of --.

Protokinetix, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Protokinetix, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Protokinetix, Inc. is more attractive than GB Sciences, Inc..

Protokinetix, Inc. has a beta of 0.614, which suggesting that the stock is 38.569% less volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.330, suggesting its more volatile than the S&P 500 by 1032.978%.

Protokinetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protokinetix, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.

Protokinetix, Inc. quarterly revenues are --, which are larger than GB Sciences, Inc. quarterly revenues of --. Protokinetix, Inc.'s net income of -$84.9K is higher than GB Sciences, Inc.'s net income of -$190.5K. Notably, Protokinetix, Inc.'s price-to-earnings ratio is 23.85x while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protokinetix, Inc. is -- versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -- compared to Protokinetix, Inc.'s net margin of -135.28%. Protokinetix, Inc.'s return on equity of -111.59% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Protokinetix, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 254.52%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Protokinetix, Inc..

Protokinetix, Inc. has a beta of 0.614, which suggesting that the stock is 38.569% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

Protokinetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protokinetix, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Protokinetix, Inc. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Protokinetix, Inc.'s net income of -$84.9K is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Protokinetix, Inc.'s price-to-earnings ratio is 23.85x while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protokinetix, Inc. is -- versus 3.40x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Protokinetix, Inc.'s net margin of -316.61%. Protokinetix, Inc.'s return on equity of -111.59% beat Plus Therapeutics, Inc.'s return on equity of --.

Protokinetix, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2040.08%. Given that Plus Therapeutics, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Protokinetix, Inc..

Protokinetix, Inc. has a beta of 0.614, which suggesting that the stock is 38.569% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Protokinetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protokinetix, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Protokinetix, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Protokinetix, Inc.'s net income of -$84.9K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Protokinetix, Inc.'s price-to-earnings ratio is 23.85x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protokinetix, Inc. is -- versus 4.12x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -- compared to Protokinetix, Inc.'s net margin of 15.59%. Protokinetix, Inc.'s return on equity of -111.59% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Protokinetix, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $42.3571 which suggests that it could grow by 38.42%. Given that Travere Therapeutics, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than Protokinetix, Inc..

Protokinetix, Inc. has a beta of 0.614, which suggesting that the stock is 38.569% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.33%.

Protokinetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protokinetix, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Protokinetix, Inc. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Protokinetix, Inc.'s net income of -$84.9K is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Protokinetix, Inc.'s price-to-earnings ratio is 23.85x while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protokinetix, Inc. is -- versus 6.37x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.